A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Dore, David D ^a,b   Ziyadeh, Najat ^b   Cai, Bin ^c   Clifford, C R ^b   Norman, Heather ^b   Seeger, John D ^b,d  

^a BROWN UNIVERSITY   (United States)

^b OPTUM   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Asthma; Chronic; Claims data; Long acting beta agonis; Obstructive pulmonary disease; Risk management, Off label prescribing

Indexed keywords

ARFORMOTEROL; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; SALMETEROL; TRIAMCINOLONE; XANTHINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGED; AGING; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTIVE VALUE; UNITED STATES; MIDDLE AGED; OFF LABEL DRUG USE; STATISTICS; YOUNG ADULT;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; OFF-LABEL USE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; YOUNG ADULT;

EID: 84899133482     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-47     Document Type: Article

References (14)

1. Serevent Diskus Prescribing Information. GlaxoSmithKline. 2010, Available from: http://www.serevent.com/ - prescribing-info. Accessed 22 December 2011.
2. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. 10.1378/chest.129.1.15, 16424409.
3. Anderson HR, Ayres JG, Sturdy PM, Bland JM, Butland BK, Peckitt C, Taylor JC, Victor CR. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005, 330:117. 10.1136/bmj.38316.729907.8F, 544425, 15618231.
4. RISK EVALUATION AND MITIGATION STRATEGY (REMS). NDA 020692 SEREVENT® DISKUS®. GlaxoSmithKline. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021077s047,021254s016,020692s039ltr.pdf. Accessed 22 December 2011.
5. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The Risks and Benefits of Indacaterol - The FDA's Review. New Engl J Med 2011, 365:2247-2249. 10.1056/NEJMp1109621, 22168640.
6. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR 2002, 51:1-16.
7. Busse WW, Lemanske RF. Asthma. New Engl J Med 2001, 344:350-362. 10.1056/NEJM200102013440507, 11172168.
8. Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res 2011, 11:43. 10.1186/1472-6963-11-43, 3050697, 21345188.
9. Dombkowski KJ, Lamarand K, Dong S, Perng W, Clark SJ. Using Medicaid claims to identify children with asthma. J Public Health Manag Pract 2012, 18:196-203. doi:10.1097/PHH.0b013e31821a3fa7, 10.1097/PHH.0b013e31821a3fa7, 22473110.
10. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2007). http://www.goldcopd.org. Accessed on 14 July 2009, Global Initiative for Chronic Obstructive Lung Disease.
11. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program, Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007, Full Report 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed 15 July 2009, National Heart, Lung, and Blood Institute.
12. Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, Earnest DL, Seeger JD. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol Ther 2010, 15:151-157. 10.1177/1074248409360357, 20200325.
13. Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. Pharmacoepidemiol Drug Saf 2011, 20:209-213. 10.1002/pds.2077, 21254293.
14. Jurek AM, Greenland S, Maldonado G. How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null?. Int J Epidemiol 2008, 37:382-385. 10.1093/ije/dym291, 18184671.